Dec 31, 2023

Arcturus Therapeutics Q4 2023 Earnings Report

Total Revenue
$34M
Previous year: $160M
-78.8%
EPS
-$0.32
Previous year: $4.33
-107.4%
R&D Expenses
$36.6M
G&A Expenses
$12.5M
Gross Profit
$30.9M
Previous year: $160M
-80.8%
Cash and Equivalents
$347M
Previous year: $392M
-11.5%
Free Cash Flow
-$1.5M
Previous year: $156M
-101.0%
Total Assets
$429M
Previous year: $450M
-4.7%

Arcturus Therapeutics

Arcturus Therapeutics